Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Europe Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-like peptide-1 (GLP-1), Pens and Needles, and Others)
- Report Code : BMIRE00027243
- Pages : 202
The insulin market in Europe is expected to grow from US$ 20,823.35 million in 2022 to US$ 38,279.77 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.
Increase in Incidence of Diabetes Bolsters Europe Insulin Market
Diabetes, a life-threatening chronic disease with no specialized cure, is mainly caused by the body’s incapacity to produce or effectively utilize the hormone insulin. This incapacity prevents the body from adequately regulating blood glucose levels. The incidence and prevalence of diabetes are rapidly increasing across Europe. Type 2 diabetes is the most prevalent form of diabetes and has grown alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to the International Diabetes Federation (IDF), ~537 million people were living with diabetes in 2021, and the number is expected to reach 643 million by 2030 and 783 million by 2045. Diabetes increases the risk of premature death of individuals by leading to complications in several body parts. Primary complications include heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Patients who have diabetes require frequent monitoring and external insulin administration. Thus, the rising prevalence of diabetes is driving the growth of the insulin market in Europe.
Market Overview
The Europe insulin market is subsegmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. The growth of the market in this region is expected to be the second largest after Germany. The prevalence of diabetes among all age groups in Europe is surging with the going commonness of obesity, unhealthy diet, and lacking physical inactivity. The prevalence of autoimmune type 1 Diabetes is rising in the region. Moreover, technologies such as insulin pumps, insulin pens, and continuous glucose monitoring devices are gaining significant acceptance in Europe. Europe has the world’s highest number of children with type 1 Diabetes. Type 1 diabetes is highly prevalent among children in the UK, Russia, and Germany. According to International Diabetes Federation (IDF), Germany has 7 million people diagnosed with diabetes, and it estimates that ~1.3 million people are expected to be living with undetected diabetes. According to the German Diabetes Centre (DDZ), diabetes would affect 12 million in the country by the end of 2040, and type 2 diabetes is anticipated to be a more prevalent type during the period.
Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)
Europe Insulin Market Segmentation
The Europe insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.
Based on long acting insulin, the Europe insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.
Based on short acting insulin and traditional human insulin, the Europe insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
Based on concentrated insulin and combination insulin, the Europe insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.
Based on biosimilar insulin, the Europe insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2022.
Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Insulin Market – By Type
1.3.2 Europe Insulin Market – By Country
2. Europe Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Insulin Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.2.1 Expert Opinion
5. Europe Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– Europe Analysis
6.1 Europe Insulin Market Revenue Forecast and Analysis
7. Europe Insulin Market Analysis – By Type
7.1 Overview
7.2 Europe Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Insulin Market – Country Analysis
8.1 Overview
8.1.1 Europe: Insulin Market, by Country, 2021 & 2028 (%)
8.1.1.1 Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.1 Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.2 Germany: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.1.2.1 Germany: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.2 Germany: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.3 Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.4 Germany: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.5 Germany: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.2 France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.1 France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.2 France : Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.2.2.1 France : Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.2 France : Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.3 France : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.4 France : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.5 France : Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.3 UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.1 UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.2 UK: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.3.2.1 UK: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.2 UK: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.3 UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.4 UK: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.5 UK: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.4 Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.1 Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.2 Italy: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.4.2.1 Italy: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.4.2.2 Italy: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.4.2.3 Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.4 Italy: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.5 Italy: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.5 Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.5.1 Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.5.2 Spain: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.5.2.1 Spain: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.5.2.2 Spain: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.5.2.3 Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.5.2.4 Spain: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.5.2.5 Spain: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.6 Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.6.1 Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.6.2 Rest of Europe: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.6.2.1 Rest of Europe: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.6.2.2 Rest of Europe: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.6.2.3 Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.6.2.4 Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.6.2.5 Rest of Europe: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
9. Europe Insulin Market–Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Adocia
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 GlaxoSmithKline plc.
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Sanofi
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Pfizer Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Merck & Co., Inc.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)
Table 2. Germany: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 4. Germany: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 5. Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 8. France: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. France : Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 10. France : Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 11. France : Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 12. France : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. France : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 14. UK: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. UK: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 16. UK: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 17. UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 18. UK: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. UK: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 20. Italy: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 21. Italy: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 22. Italy: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 23. Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 24. Italy: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 25. Italy: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 26. Spain: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 27. Spain: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 28. Spain: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 29. Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 30. Spain: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 31. Spain: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 32. Rest of Europe: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 33. Rest of Europe: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 34. Rest of Europe: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 36. Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 37. Rest of Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 38. Organic Developments in the Insulin Market
Table 39. Inorganic Developments in the Insulin Market
Table 40. Glossary of Terms, Insulin Market
LIST OF FIGURES
Figure 1. Europe Insulin Market Segmentation
Figure 2. Europe Insulin Market Segmentation, By Country
Figure 3. Europe Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Germany Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe PEST Analysis
Figure 7. Expert Opinion
Figure 8. Europe Insulin Market Impact Analysis of Drivers and Restraints
Figure 9. Europe Insulin Market– Revenue Forecast and Analysis
Figure 10. Europe Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 11. Europe Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Europe Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Europe Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Europe Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Europe Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Europe Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Europe Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Europe Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Europe Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Europe Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Europe Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Europe Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Europe Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Europe Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Europe Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Europe Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Europe Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Europe Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Europe Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Europe Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Europe Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Europe: Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 38. Europe: Insulin Market, by Country, 2021 & 2028 (%)
Figure 39. Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe insulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Europe insulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – Europe Insulin Market
● Adocia
● Biocon
● Eli Lilly and Company
● GlaxoSmithKline plc.
● Merck & Co., Inc.
● Novo Nordisk A/S
● Pfizer Inc.
● Sanofi
● Tonghua Dongbao Pharmaceutical Co., Ltd.
● Wockhardt
At 10.6% CAGR, the Europe Insulin Market is speculated to be worth US$ 38,279.77 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the Europe insulin market was valued at US$ 20,823.35 million in 2022 and is expected to reach US$ 38,279.77 million by 2028, registering an annual growth rate of 10.6% from 2022 to 2028. Rapid technological developments in insulin delivery devices by major players and increase in incidence of diabetes are the critical factors attributed to the market expansion.
Products with advanced insulin technology with more effective benefits are a major requirement in the treatment of diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing across region, the demand for more advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.
A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:
• In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial initiated in China.
• In May 2021, Bigfoot Biomedical received 510(k) clearance by USFDA for its Bigfoot Unity Diabetes Management System, which features connected smartpen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.
Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the Europe insulin market.
On the contrary, risks associated with insulin delivery devices hurdles the growth of Europe insulin market.
Based on type, the Europe insulin market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment held 26.8% market share in 2022, amassing US$ 5,572.01 million. It is projected to garner US$ 10,347.48 million by 2028 to expand at 10.9% CAGR during 2022–2028.
Based on long acting insulin, the Europe insulin market is sub-segmented into levemir, lantus, basaglar, and tresiba. The tresiba segment held 49.3% market share in 2022, amassing US$ 2,748.44 million. It is projected to garner US$ 5,221.51 million by 2028 to expand at 11.3% CAGR during 2022–2028.
Based on rapid acting insulins the Europe insulin market is sub-segmented into novolog, humalog, admelog, and others. The humalog segment held 48.1% market share in 2022, amassing US$ 1,582.93 million. It is projected to garner US$ 2,928.32 million by 2028 to expand at 10.8% CAGR during 2022–2028.
Based on short acting insulin and traditional human insulin, the Europe insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held 47.9% market share in 2022, amassing US$ 1,751.97 million. It is projected to garner US$ 3,064.88 million by 2028 to expand at 9.8% CAGR during 2022–2028.
Based on concentrated insulin and combination insulin, the Europe insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held 42.9% market share in 2022, amassing US$ 379.11 million. It is projected to garner US$ 679.67 million by 2028 to expand at 10.2% CAGR during 2022–2028.
Based on biosimilar insulin, the Europe insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held 63.3% market share in 2022, amassing US$ 615.15 million. It is projected to garner US$ 1,563.73 million by 2028 to expand at 16.8% CAGR during 2022–2028.
Based on country, the Europe insulin market is segmented into UK, Germany, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 6,132.48 million in 2022 and is likely to hit US$ 11,020.74 million by 2028, exhibiting a CAGR of 10.3% during the forecast period.
Key players dominating the Europe insulin market are Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt among others.
In 2021, Adocia announced today that its partner Tonghua Dongbua Pharmaceutical Co. Ltd. received the clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 clinical trial of BioChaperone Lispro, and Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes. In 2020, Pfizer showcased Phase I data from a study assessing PF-06882961, an oral small molecule glucagon-like peptide – 1 receptor (GLP-1 R) agonist in type 2 diabetes patients that showed significant promise in the reduction of glucose levels and body weight.
Related Reports
- $3,000.00 – $5,000.00
